尼可地尔联合芪苈强心胶囊治疗慢性肺心病伴冠心病心衰的效果  

The Effectiveness of Nicorandil Combined with Qili Qiangxin Capsules in the Treatment of Chronic Pulmonary Heart Disease with Coronary Heart Disease and Heart Failure

作　　者：郭志国 GUO Zhi-guo(Sheqi County People's Hospital,Sheqi,Henan 473300,China)

机构地区：[1]社旗县人民医院,河南社旗473300

出　　处：《黔南民族医专学报》2025年第1期8-12,共5页Journal of Qiannan Medical College for Nationalities

摘　　要：目的:明确尼可地尔联合芪苈强心胶囊治疗慢性肺心病伴冠心病心衰的价值。方法:将本院2021年4月至2023年3月期间收治的90例慢性肺心病伴冠心病心衰患者采用随机数字表法分为两组,每组各45例;单一组给予尼可地尔治疗,联合组在采用尼可地尔加芪苈强心胶囊治疗;以临床疗效、心功能、凝血功能及不良反应等为评价指标,对比两组的治疗效果。结果:联合组总有效率高于单一组(P<0.05);联合组左心室射血分数(LVEF)、每搏输出量(SV)高于单一组(P<0.05),舒张末期半径(LVEDD)、左室收缩末半径(LVESD)低于单一组(P<0.05);联合组抗凝血酶Ⅲ(ATⅢ)、纤维蛋白原(Fbg)和D-二聚体(D-D)低于单一组(P<0.05);两组不良反应发生率对比无差异(P>0.05)。结论:应用尼可地尔联合芪苈强心胶囊治疗肺心病伴冠心病心衰的效果显著,具有推广价值。Objective:To evaluate the efficacy of nicorandil combined with Qili Qiangxin Capsules in the treatment of chronic pulmonary heart disease with coronary heart disease and heart failure.Methods:A total of 90 patients with chronic pulmonary heart disease accompanied by coronary heart disease and heart failure admitted to our hospital from April 2021 to March 2023 were randomly divided into two groups,with 45 patients in each group.The monotherapy group received nicorandil treatment,while the combination therapy group received nicorandil plus Qili Qiangxin Capsules.Clinical efficacy,cardiac function,coagulation function,and adverse reactions were evaluated to compare the therapeutic effects between the two groups.Results:The total effective rate in the combination therapy group was higher than that in the monotherapy group(P<0.05).The left ventricular ejection fraction(LVEF)and stroke volume(SV)were higher in the combination therapy group than in the monotherapy group(P<0.05),while the left ventricular end-diastolic diameter(LVEDD)and left ventricular end-systolic diameter(LVESD)were lower(P<0.05).The levels of antithrombin III(ATIII),fibrinogen(Fbg),and D-dimer(D-D)were lower in the combination therapy group compared to the monotherapy group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The use of nicorandil combined with Qili Qiangxin Capsules in the treatment of pulmonary heart disease accompanied by coronary heart disease and heart failure demonstrates significant efficacy and holds potential for clinical promotion.

关 键 词：尼可地尔 芪苈强心胶囊 慢性肺心病 冠心病心衰 心功能 

分 类 号：R54[医药卫生—心血管疾病]